搜索
Leap Therapeutics Inc
LPTX添加自选
2.050USD
0.0000.00%
交易中 （美东）报价延迟15分钟
68.57M总市值
亏损市盈率 TTM
关于 Leap Therapeutics Inc 公司
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc简介
公司代码LPTX
公司名称Leap Therapeutics Inc
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
员工数量52
证券类型Ordinary Share
年结日Jan 24
公司地址47 Thorndike Street
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02142
电话16172524343
网址https://www.leaptx.com/
公司代码LPTX
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
常见问题
Leap Therapeutics Inc的前五大股东是谁？
Leap Therapeutics Inc 的前五大股东如下：Dr. James H. Cavanaugh, Ph.D.
有多少机构持有Leap Therapeutics Inc(LPTX)的股份？
截至2026Q1，共有114家机构持有Leap Therapeutics Inc的股份，合计持有的股份价值约为11.73M，占公司总股份的12.01%。与2025Q4相比，机构持股有所增加，增幅为-9047212.00。